August 7, 2014 New York Times: Prostate Screening Still Not Recommended for All
Deepak Kapoor is founder of IMF, Chairman and CEO Integrated Medical Professionals, PLLC, and Clinical Associate Professor of Urology Icahn School of Medicine at Mount Sinai
Here is his comment:
The ERSPC study finds that that men screened for prostate cancer were 27% less likely to die from their disease then those who were unscreened. Importantly, the survival benefits for patients screened for prostate cancer becomes more significant the longer patients are followed, which supports the notion that early detection of this disease saves lives. Indeed, these are precisely the findings we have seen in the United States – since the advent of PSA testing, the 10 year survival rates for prostate cancer has increased from 50% to over 99% while the death rate has decreased by nearly 40%.
Urologists and other physicians who care for men stricken with prostate cancer are well aware of the need to target diagnostic and treatment efforts to those men at greatest risk – that’s why Advanced Urology Centers of New York supports international screening guidelines that targets testing to where it will do the most good. Screening for prostate cancer simply provides a man with information to help them make informed decisions regarding their own health – it is not a commitment to undergo treatment. We strongly agree with the view presented by the authors of the study, that “early diagnosis cannot be refused to men who are well informed and request to be tested.” To that end, all men should have a conversation with their physician on their risk factors and whether testing for prostate cancer is right for them.
Deepak A. Kapoor M.D.
Chairman and CEO
Integrated Medical Professionals, PLLC
Clinical Associate Professor of Urology
Icahn School of Medicine at Mount Sinai